What can we learn from oncology surgical trials?

Nature Reviews Clinical Oncology

Volumn 13, Issue 1, 2016, Pages 55-62

  Evrard, Serge ^a   McKelvie Sebileau, Pippa ^a   Van De Velde, Cornelis ^b   Nordlinger, Bernard ^c   Poston, Graeme ^d  

^a INSTITUT BERGONIÉ   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HÔPITAL AMBROISE PARÉ   (France)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGE; ANATOMICAL VARIATION; BODY MASS; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON RESECTION; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; FITNESS; FUNDING; GASTRECTOMY; HUMAN; INTERVENTION STUDY; LAPAROSCOPY; LIVER RESECTION; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MEDICAL AUDIT; MEDICAL PRACTICE; MEDICAL SPECIALIST; METHODOLOGY; ONCOLOGY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION; STOMACH CANCER; SURGICAL ONCOLOGY; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT FAILURE; BREAST NEOPLASMS; CANADA; EARLY DIAGNOSIS; INTERDISCIPLINARY COMMUNICATION; MORTALITY; NEOPLASMS; SURVIVAL;

BREAST NEOPLASMS; CANADA; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84951907152     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.176     Document Type: Review

References (77)

1. Wyld, L., Audisio, R. A. & Poston, G. J. The evolution of cancer surgery and future perspectives. Nat. Rev. Clin. Oncol. 12, 115-124 (2015).
2. Poston, G. J. in Textbook of Surgical Oncology (eds Poston, G. J., Beauchamp, R. D. & Ruers, T.) 1-4 (Informa Healthcare, 2007).
3. Philip, J. F. Results of treatment of breast cancer at Aberdeen Royal Infirmary 1940-55. Br. Med. J. 1, 323-331 (1967).
4. Cancer Research UK. Cancer Statistics, Key Facts: All Cancers Combined, February 2015 [online], http://publications.cancerresearchuk.org/downloads/Product/CS-KF-ALLCANCERS.pdf (2015).
5. McCulloch, P., Taylor, I., Sasako, M., Lovett, B. & Griffin, D. Randomised trials in surgery: problems and possible solutions. BMJ 324, 1448-1451 (2002).
6. Ergina, P. L. et al. Challenges in evaluating surgical innovation. Lancet 374, 1097-1104 (2009).
7. Balch, C. M., Durant, J. R. & Bartolucci, A. A. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann. Surg. 198, 164-167 (1983).
8. [No authors listed] Surgical research: The reality and the IDEAL. Lancet 374, 1037 (2009).
9. McCulloch, P. et al. No surgical innovation without evaluation: The IDEAL recommendations. Lancet 374, 1105-1112 (2009).
10. Solomon, M. J. & McLeod, R. S. Clinical studies in surgical journals-have we improved? Dis. Colon Rectum 36, 43-48 (1993).
11. Weil, R. J. The future of surgical research. PLoS Med. 1, e13 (2004).
12. Panesar, S. S., Thakrar, R., Athanasiou, T. & Sheikh, A. Comparison of reports of randomized controlled trials and systematic reviews in surgical journals: literature review. J. R. Soc. Med. 99, 470-472 (2006).
13. Martling, A., Cedermark, B., Johansson, H., Rutqvist, L. E. & Holm, T. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br. J. Surg. 89, 1008-1013 (2002).
14. McArdle, C. S. & Hole, D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 302, 1 501-1505 (1991).
15. Farrokhyar, F. et al. Randomized controlled trials of surgical interventions. Ann. Surg. 251, 409-416 (2010).
16. Bonenkamp, J. J. et al. Extended lymph-node dissection for gastric cancer. N. Engl. J. Med. 340, 908-914 (1999).
17. Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M. & van de Velde, C. J. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11, 439-49 (2010).
18. Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
19. Abraham, I., Dhar, P. & Praseedom, R. K. Adjuvant chemoradiotherapy for gastric cancer. N. Engl. J. Med. 346, 210-211 (2002).
20. Cuschieri, A. Does chemoradiotherapy after intended curative surgery increase survival of gastric cancer patients? Gut 50, 751 (2002).
21. Chapman, S. J. et al. Discontinuation and non-publication of surgical randomised controlled trials: observational study. BMJ 349, g6870 (2014).
22. Denost, Q. et al. Perineal transanal approach: A new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. Ann. Surg. 260, 993-999 (2014).
23. Ruers, T. et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). Ann. Oncol. 23, 2619-2626 (2012).
24. Ruers, T. et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-Term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) [abstract]. J. Clin. Oncol. 33 (Suppl.), a3501 (2015).
25. Lamont, E. B. et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J. Natl Cancer Inst. 95, 1370-1375 (2003).
26. Pugh, S. A. et al. Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001351 (2015).
27. Olson, J. A. Jr et al. American College of Surgeons Oncology Group Trials Z0010 and Z0011. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J. Clin. Oncol. 26, 3530-3535 (2008).
28. Caudle, A. S. et al. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: A practice-changing trial. Ann. Surg. Oncol. 18, 2407-2412 (2011).
29. Caudle, A. S. et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann. Surg. Oncol. 19, 3144-3151 (2012).
30. Alliance for Clinical Trials in Oncology. Our vision [online], https://www.allianceforclinicaltrials inoncology.org (2015).
31. American College of Surgeons Oncology Group and Radiation Therapy Oncology Group: ACOSOG Z4099/RTOG 1021. A randomized phase III stu dy of sublobar resection (+/-brachytherapy) versus stereotactic body radiation therapy in high risk patients with stage I non-small cell lung cancer (NSCLC) http://atc.wustl.edu/protocols/rtog/1021/Z4099-1021-A0-05-02-2011 (2011)
32. Alliance for Clinical Trials in Oncology. Alliance study result summaries [online], https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic% 2FResults (2015).
33. European Organisation for Research and Treatment of Cancer. Clinical Trials Database [online], http://www.eortc.org/clinical-Trials/(2015).
34. Jacquier, I., Boutron, I., Moher, D., Roy, C. & Ravaud, P. The reporting of randomized clinical trials using a surgical intervention is in need of immediate improvement: A systematic review. Ann. Surg. 244, 677-683 (2006).
35. National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA176]: Cetuximab for the first-line treatment of metastatic colorectal cancer [online], https://www.nice.org.uk/guidance/ta176
36. Naredi, P. & La Quaglia, P. The future of trials in surgical oncology. Nat. Rev. Clin. Oncol. 12, 425-431 (2015).
37. [No authors listed] The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can. Med. Assoc. J. 121, 1193-1254 (1979).
38. Sackett, D. L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95 (2 Suppl.), 2S-4S (1989).
39. Adam, R. et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol. 27, 1829-1835 (2009).
40. Brouquet, A. et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J. Clin. Oncol. 29, 1083-1090 (2011).
41. Elias, D. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. 28, 63-68 (2010).
42. Curley, S. A. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? Ann. Surg. Oncol. 15, 11-13 (2008).
43. Barkun, J. S. et al. Evaluation and stages of surgical innovations. Lancet 374, 1089-1096 (2009).
44. Köckerling, F. The need for registries in the early scientific evaluation of surgical innovations. Front. Surg. 1, 12 (2014).
45. Schadde, E. et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann. Surg. 260, 829-836 (2014).
46. Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M. & Maron, D. J. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007).
47. Benson, K. & Hartz, A. J. A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342, 1878-1886 (2000).
48. Concato, J., Shah, N. & Horwitz, R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000).
49. [No authors listed] Quality assurance in surgical oncology: The EURECCA polatform. Eur. J. Surg. Oncol. 40, 1387-1390 (2014).
50. Moher, D. et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int. J. Surg. 10, 28-55 (2012).
51. Moher, D. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA 279, 1489-1491 (1998).
52. Boutron, I., Moher, D., Altman, D. G., Schulz, K. F. & Ravaud, P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann. Intern. Med. 148, 295-309 (2008).
53. Nagendran, M. et al. Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacological treatments (NPT): A cross-sectional study. BMJ Open 3, e003898 (2013).
54. Clavien, P. A. & Lillemoe, K. D. A new policy to implement CONSORT guidelines for surgical randomized controlled trials. Ann. Surg. 260, 947-948 (2014).
55. Lacy, A. M. et al. Laparoscopy-Assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: A randomised trial. Lancet 359, 2224-2229 (2002).
56. Evrard, S., Mathoulin-Pelissier, S. & Kramar, A. Open versus laparoscopy-Assisted colectomy. Lancet 361, 73-76 (2003).
57. Buunen, M. et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-Term outcome of a randomised clinical trial. Lancet Oncol. 10, 44-52 (2009).
58. Kitchener, H., Swart, A. M., Qian, Q., Amos, C. & Parmar, M. K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 373, 125-136 (2009).
59. Barton, D. P., Naik, R. & Herod, J. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomized study. Int. J. Gynecol. Cancer 19, 1465 (2009).
60. Nordlinger, B., Poston, G. J. & Goldberg, R. M. Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J. Clin. Oncol. 33, 241-243 (2015).
61. Primrose, J. et al. Systemic chemotherapy with or without cetuximab in patients with respectable colorectal liver metastases: The New EPOC randomised controlled trial. Lancet Oncol. 15, 601-611 (2014).
62. Evrard, S. et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br. J. Surg. 99, 558-565 (2012).
63. McCulloch, P. et al. IDEAL framework for surgical innovation 1: The idea and development stages. BMJ 346, f3012 (2013).
64. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1-10 (1989).
65. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01876901?term=Cascador&rank=1 (2015).
66. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02218801 (2015).
67. [No authors listed] Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336, 980-987 (1997).
68. Peeters, K. C. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693-701 (2007).
69. den Dulk, M. et al. The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur. J. Cancer 45, 1175-1183 (2009).
70. Nordlinger, B. et al. Perioperative chemotherapy with FOLFOX4 and surgery for resectable liver metastases from colorectal cancer. Lancet 371, 1007-1016 (2008).
71. Kapiteijn, E. et al. Perioperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
72. van Gijn, W. et al. Volume and outcome in colorectal cancer surgery. Eur. J. Surg. Oncol. 36 (Suppl. 1), S55-S63 (2010).
73. den Dulk, M. et al. Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. Eur. J. Cancer 44, 1710-1716 (2008).
74. Krijnen P, den Dulk, M., Meershoek-Klein-Kranenbarg, E., Jansen-Landheer, M. L. & van de Velde, C. J. Improved survival after resectable non-cardia gastric cancer in The Netherlands: The importance of surgical training and quality control. Eur. J. Surg. Oncol. 35, 715-720 (2009).
75. West, N. P. et al. Pathology grading of colon cancer surgical resection and its association with survival: A retrospective observational study. Lancet Oncol. 9, 857-865 (2008).
76. Quirke, P. et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373, 821-828 (2009).
77. Taylor, F. G. et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J. Clin. Oncol. 32, 34-43 (2014).